Search

Diane Shader Smith and Mark Smith have established Mallory's Legacy Fund. Their daughter Mallory was one of the first cystic fibrosis patients to receive phage therapy (and she inspired Phage Directory's start!). Donations will support phag

Ameneh Khatami (University of Sydney) and colleagues published a new preprint showing therapeutic monitoring of the host-bacterium-phage interaction in a child. They describe how they treated a 7-year-old with a chronic osteoarticular Pseud

The WHO's 4th Clinical Antibacterial Pipeline Advisory Group Meeting took place this week. Haileyesus Getahun, MD (Joint Secretariat on AMR at WHO) stated via Twitter that for the first time, available data on phage therapy was set to be ev

We are urgently seeking Extended Spectrum Beta-Lactamase (ESBL) E. coli phages for a cystic fibrosis patient in the USA. Ways to help at this stage: - By sending your phages for testing on the patient's strain - By receiving the strain an

We are urgently seeking Extended Spectrum Beta-Lactamase (ESBL) E. coli phages for a cystic fibrosis patient in the USA. Ways to help at this stage: - By sending your phages for testing on the patient's strain - By receiving the strain an

The Jaschke lab at Macquarie University (Sydney, Australia) has an opening for a PhD student to work within a multidisciplinary team on a cutting-edge NHMRC-funded project at the intersection of synthetic biology and phage therapy: engineer

Earlier this month we posted that Adaptive Phage Therapeutics received emergency FDA authorization to treat a group of COVID-19 patients in Texas with A. baumannii infections. Now, they've received expanded access authorization to use their

Ruby Lin (Wesmead Institute for Medical Research, Australia) and colleagues published a Nature Microbiology blog post on their work toward establishing an Australian Phage Network. This post follows up on their Nature Microbiology paper fro

Fernando Gordillo Altamirano and Jeremy Barr (Monash University) published a new perspective in Current Opinion in Biotechnology entitled "Unlocking the next generation of phage therapy: the key is in the receptors". They argue that identif

We are urgently seeking Serratia marcescens phages for a patient. Ways to help at this stage: - By sending your phages for testing on the patient's strain - By receiving the strain and testing your phages - By receiving the strain and usi

We are urgently seeking Serratia marcescens phages for a patient. Ways to help at this stage: - By sending your phages for testing on the patient's strain - By receiving the strain and testing your phages - By receiving the strain and usi

Adaptive Phage Therapeutics has deployed their PhageBank™ in Texas to treat COVID-19 patients suffering from life-threatening carbapenem resistant Acinetobacter baumannii (CRAB). Eight of these patients have so far received PhageBank™ thera

BiomX has announced the dosing of their first subject in their Phase 1a clinical study testing the safety, pharmacokinetics and oral delivery of a phage therapy candidate for treatment of Inflammatory Bowel Disease. Results are expected in

Patients in India in need of phage therapy used to have to ship their samples internationally for phage susceptibility testing, which was a dealbreaker for even phage-friendly doctors as this was slow and expensive. Now, they can do it loca

Adaptive Phage Therapeutics (APT) has received Orphan drug designation from the FDA for the use of its PhageBank™ (a continually expanding library of phages) to treat prosthetic joint infections. APT will now be eligible for seven years of

The FDA has authorized Armata Pharmaceuticals to initiate a phase 1b/2a clinical trial, which they are calling "SWARM-P.a.", to test AP-PA02, its lead phage cocktail candidate, against Pseudomonas aeruginosa airway infections in cystic fibr

As there is currently no gold standard for developing a phage cocktail, Melissa Haines (University of Leicester, UK) and colleagues set out to describe a novel approach to phage cocktail development by comparing different methods side by si

Saima Aslam (University of California, San Diego) and colleagues published a new paper in Open Forum Infectious Diseases showing the lessons the IPATH team has learned from their first 10 cases of IV phage therapy.

Gabriella (Ella) Balasa, a cystic fibrosis (CF) patient who has received phage therapy, and her physician, Nauman Chaudary, have co-authored a unique perspective paper in Pulmonary Therapy about the experience and treatment of a CF patient.

Ruby Prosser Scully wrote a nice phage therapy article for the Australian healthcare professional-targeted paper Medical Republic. She interviews Australian phage researchers Peter Speck, Jon Iredell and Jeremy Barr, among others who are wo